PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Saneca Pharma renews Pharmascience agreement following successful quality audit

Contract development and manufacturing organisation (CDMO) Saneca Pharma has renewed an agreement with Pharmascience Inc, one of Canada’s largest pharmaceutical companies, for the manufacture and supply of prescription medicines in tablet form.
The agreement, which follows a successful GMP audit held in January 2018, includes the manufacture of 600 million enteric, chewable and film-coated tablets (RX medicines) per year. It will also involve R&D and laboratory analyses related to existing and emerging formulations, as well as technical support in delivery to the Canadian market.
Markus Saal, sales director at Saneca Pharma said: “Pharmascience is a big name in the pharmaceutical industry, so it’s great to work with them on a project of this size.
“Saneca Pharma produces large number of tablets for customers every year and has a huge amount of expertise, especially in solid dose manufacturing. By delivering both development and manufacturing services, we’re also able to simplify the tech transfer process to commercial production and streamline our customers’ projects, saving time and costs.
“We’re confident we’ll be able to add value to this project by combining our in-depth knowledge and our wide range of capabilities.”
The substantial agreement consists of nine different stock keeping units (SKUs), covering a number of therapeutic areas.
Pierre Plante, sourcing director at Pharmascience said: “Saneca Pharma is well located in Europe and its experience in manufacturing solid dose products was a huge part of the reason we selected them as our outsourcing partner for this project.
“Its comprehensive tech-transfer offering was also interesting for us. We look forward to continuing to develop our partnership with Saneca as we move into 2018.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026